- John G. Freund, M.D. | Chairman of the Board
- Vincent J. Angotti | Chief Executive Officer and Director
- Paul L. Berns | Director
- Dennis M. Fenton, Ph.D. | Director
- Catherine J. Friedman | Director
- Jeryl L. Hilleman | Director
- William J. Rieflin | Director
- Wendell Wierenga, Ph.D. | Director
John G. Freund, M.D. | Chairman of the Board
John G. Freund has been a member of our board of directors since 1999 and our lead independent director since July 2008. He has been a managing director of Skyline Ventures, a venture capital firm specializing in healthcare companies, since 1997. From 1995 to 1997, Dr. Freund was a managing director in the private equity group at Chancellor Capital Management. AMVESCAP plc acquired Chancellor Capital Management in 1998 and renamed the division INVESCO Private Capital. In 1995, he co-founded Intuitive Surgical, Inc. From 1988 to 1994, he held various positions at Acuson Corp., most recently as executive vice president. Siemens Corp. acquired Acuson in 2000. Prior to Acuson, Dr. Freund was a general partner of Morgan Stanley Venture Partners from 1987 to 1988. From 1982 to 1988, Dr. Freund was at Morgan Stanley & Co., where he was a co-founder of the Healthcare Group in the Corporate Finance Department. He received a B.A. from Harvard College, an M.D. from Harvard Medical School and an M.B.A. from Harvard Business School. Dr. Freund was a member of the boards of directors of The New Economy Fund from 2000 to 2009, Sirtris Pharmaceuticals, Inc. from 2004 to 2008, Hansen Medical, Inc. from 2002 to 2010, MAP Pharmaceuticals, Inc. from 2004 to 2011, and MAKO Surgical Corp. from 2008 to 2013. Dr. Freund is currently a member of the boards of directors of SMALLCAP World Fund, Fundamental Investors, Inc. and The Growth Fund of America, Inc. He is also a director of Concert Pharmaceuticals, Inc., Tetraphase Pharmaceuticals, Inc. and Proteon Therapeutics, Inc.
Vincent J. Angotti | Chief Executive Officer and Director
Vincent J. Angotti was named Chief Executive Officer and joined our board of directors in October 2015. He was previously our executive vice president and chief operating officer from June 2012 to October 2015. Prior to that, Mr. Angotti was senior vice president and chief commercialization officer from May 2008 to June 2012. From 2001 to 2008, he held several positions with Reliant Pharmaceuticals, Inc., the most recent of which was senior vice president of sales and marketing. GlaxoSmithKline acquired Reliant Pharmaceuticals in 2008. Prior to Reliant Pharmaceuticals, from 1991 to 2001, Mr. Angotti held several positions at Novartis Pharmaceuticals Corporation, most recently as executive director, field operations. Mr. Angotti received a B.S. from Cornell University and an M.B.A. from Columbia University.
Paul L. Berns | Director
Paul L. Berns has been a member of our board of directors since November 2005. Since March 2014, he has served as president and chief executive officer of Anacor Pharmaceuticals, Inc. Prior to March 2014, he was a self-employed consultant to the pharmaceutical industry. From March 2006 to August 2012, he served as president, chief executive officer and a member of the board of directors of Allos Therapeutics, Inc., which was acquired by Spectrum Pharmaceuticals, Inc. in August 2012. From 2002 to 2005, Mr. Berns was chief executive officer, president and a director of Bone Care International, Inc. that was acquired by Genzyme Corporation in 2005. From 2001 to 2002, Mr. Berns served as vice president and general manager of the Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories. He served as vice president, marketing of BASF Pharmaceuticals-Knoll from 2000 to 2001. From 1990 to 2000, Mr. Berns held various positions, including senior management roles, at Bristol-Myers Squibb Company. Mr. Berns received a B.S. from the University of Wisconsin. Mr. Berns is chairman of the board of directors of Anacor Pharmaceuticals, and is a member of the board of directors of Jazz Pharmaceuticals, plc and Cellectar Biosciences, Inc.
Dennis M. Fenton, Ph.D. | Director
Dennis M. Fenton has been a member of our board of directors since August 2009. From 1982 to 2008, Dr. Fenton held numerous positions, including executive roles in process development, manufacturing, sales and marketing and research and development, at Amgen, Inc. From 2000 to 2008, Dr. Fenton was executive vice president responsible for worldwide operations, manufacturing, process development and quality. From 1995 to 2000, Dr. Fenton was senior vice president of operations, and from 1992 to 1995, Dr. Fenton was senior vice president of sales, marketing and process development for Amgen. Dr. Fenton received a B.S. in biology from Manhattan College and a Ph.D. in microbiology from Rutgers University. Dr. Fenton is a member of the board of directors of Dendreon Corporation, Hospira, Inc., Kythera Biopharmaceuticals, Inc., and Portola Pharmaceuticals, Inc. Dr. Fenton was a member of the board of directors of Genzyme Corporation from 2010 to 2011.
Catherine J. Friedman | Director
Catherine J. Friedman has been a member of our board of directors since September 2007. Ms. Friedman has been an independent financial consultant to private and public companies in the life sciences industry since 2006. Prior to that, Ms. Friedman held numerous positions over a 23-year investment banking career with Morgan Stanley & Co., including Managing Director from 1997 to 2006 and Head of West Coast Healthcare and Co-Head of the Biotechnology Practice from 1993 to 2006. Ms. Friedman received a B.A. from Harvard College and an M.B.A. from the University of Virginia Darden School of Business. Ms. Friedman is a member of the boards of directors of EnteroMedics Inc., GSV Capital Corp, and Theravance, Inc.
Jeryl L. Hilleman | Director
Jeryl L. Hilleman has been a member of our board of directors since January 2005. She has served as the chief financial officer at Intersect ENT, Inc. since June 2014. Prior to joining Intersect ENT in June 2014, she served as the chief financial officer, chief accounting officer and secretary of the biopharmaceutical company Ocera Therapeutics, Inc. Prior to joining Ocera in September 2013, Ms. Hilleman provided independent financial and strategic consulting for biotech and cleantech companies. From January 2008 to May 2012, she was chief financial officer of Amyris Biotechnologies, Inc. Prior to joining Amyris in January 2008, she was executive vice president and chief financial officer of Symyx Technologies, Inc. from 1997 to June 2007. Prior to joining Symyx in 1997, Ms. Hilleman served as vice president finance and chief financial officer of two public biotechnology companies, Geron Corporation and Cytel Corporation, which merged with Epimmune Inc. in 1999. Ms. Hilleman received an A.B. from Brown University and an M.B.A. from the Wharton Graduate School of Business.
William J. Rieflin | Director
William J. Rieflin has been a member of our board of directors since September 2010. In September 2010, Mr. Rieflin was appointed chief executive officer and a member of the board of directors of NGM Biopharmaceuticals, Inc. Mr. Rieflin previously served as our president from 2004 to September 2010. From 1996 to 2004, he held various positions with Tularik Inc., most recently as executive vice president, administration, chief financial officer, general counsel and secretary. Amgen Inc. acquired Tularik in 2004. Mr. Rieflin received a B.S. from Cornell University, an M.B.A. from the University of Chicago Graduate School of Business and a J.D. from Stanford Law School. Mr. Rieflin is the lead independent member of the board of directors of Anacor Pharmaceuticals, Inc.
Wendell Wierenga, Ph.D. | Director
Wendell Wierenga has been a member of our board of directors since 2000. From June 2011 to February 2014, he served as executive vice president, research and development at Santarus, Inc. that was acquired by Salix Pharmaceuticals, Ltd. in January 2014. Prior to joining Santarus, Dr. Wierenga was executive vice president of research and development at Ambit Biosciences, Inc. from January 2007 to May 2011. Dr. Wierenga was executive vice president of research and development at Neurocrine Biosciences, Inc. from 2003 to 2007. From 2000 to 2003, Dr. Wierenga was chief executive officer of Syrrx, Inc. Prior to joining Syrrx, from 1990 to 2000, he was senior vice president of worldwide pharmaceutical sciences, technologies and development at Parke-Davis, a division of Warner Lambert Co. Pfizer Inc. acquired Warner Lambert in 2000. Prior to Parke-Davis, Dr. Wierenga worked at Upjohn Co., later Pharmacia & Upjohn, Inc. for 16 years in various positions, most recently as executive director of discovery research. Pfizer acquired Pharmacia & Upjohn, then named Pharmacia Corp., in 2002. Dr. Wierenga is currently a member of the board of directors of Cytokinetics, Inc., Ocera Therapeutics, Concert Pharmaceuticals, Inc., Apricus Biosciences, Inc. and Anacor Pharmaceuticals, Inc. From 1996 to 2013, Dr. Wierenga was a member of the board of directors of Onyx Pharmaceuticals, Inc. that was acquired by Amgen in 2013. Dr. Wierenga received a B.S. from Hope College and a Ph.D. in chemistry from Stanford University.